Eye diseases – Web Xpress http://web-xpress.com/ Mon, 29 Nov 2021 21:56:08 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://web-xpress.com/wp-content/uploads/2021/10/icon-9-150x150.png Eye diseases – Web Xpress http://web-xpress.com/ 32 32 [Postponed] Emerging Technologies Are Changing Access to Ophthalmology and Point of Care | Webinars https://web-xpress.com/postponed-emerging-technologies-are-changing-access-to-ophthalmology-and-point-of-care-webinars/ Mon, 29 Nov 2021 21:52:09 +0000 https://web-xpress.com/postponed-emerging-technologies-are-changing-access-to-ophthalmology-and-point-of-care-webinars/ Wed Dec 1 2021 10: 00A EST Presented by ABOUT THIS WEBINAR This webinar has been postponed due to technical difficulties at Photonics Media. Please stay tuned for the new date! The increase in cases of eye disorders is expected to drive the growth of the global ophthalmic diagnostics and surgical devices market. To support […]]]>

Wed Dec 1 2021 10: 00A EST

Presented by

ABOUT THIS WEBINAR

This webinar has been postponed due to technical difficulties at Photonics Media. Please stay tuned for the new date!


The increase in cases of eye disorders is expected to drive the growth of the global ophthalmic diagnostics and surgical devices market. To support this growing demand, new innovations will help practitioners achieve immediate results to improve diagnostic accuracy and treatment selection.

This webinar – for those interested in visual optics, ophthalmology and biomedical devices – showcases five technologies that use optics, photonics or imaging to redefine the way patients are served across the board. along the continuum from point of care, diagnosis and treatment to surgical and corrective selection. It also shows how technologies are applied to make tools more mobile and accessible, minimize workflows, and reduce risks associated with COVID-19 to dramatically improve the experience for patients and practitioners.

Participants will learn how to:

  1. Intelon Optics High Resolution Contactless BOSS ™ (Brillouin Optical Scanner System) creates three-dimensional corneal “stiffness” maps to diagnose weakened tissue in and around the cornea and lens, and to determine if a patient is a good candidate for refractive surgery or corneal.
  2. The OVITZ xwave aberrometer, coupled with proprietary software, allows ophthalmologists to prescribe personalized scleral contact lenses to patients with higher order visual aberrations that cannot be treated with commercial contact lenses.
  3. The AkknaTek Lens Examiner identifies the displacement of intraocular lenses (IOLs) after surgery, allowing ophthalmologists to intervene and realign the lenses before the eye is fully healed.
  4. Lumedica Vision Economical OQ EyeScope detects subterranean retinal disease years before symptoms appear, and does so at one-third the cost of large stationary spectral domain optical coherence tomography systems.
  5. 2EyesVision SimVis Gekko allows patients to try out different types of multifocal IOLs before committing to surgery.

The technologies will be covered in five minute presentations, followed by a panel discussion. Questions from participants will be taken into account.

Who should be present:

This webinar is for anyone interested in visual optics, ophthalmology and biomedical devices. This includes R&D scientists, corporate directors and consultants, and others involved in medical imaging market research, purchasing, design and manufacturing.


About the presenters:

Sujatha Ramanujan, Ph.D., is CEO of Luminate and moderator of this event. She is a serial entrepreneur, having started and developed three start-up companies in cardiac surgery equipment, optical communications and nanomaterials. As CTO and product line manager of mammography and pediatric CAD activities within Kodak and Carestream, she and her team have developed and launched clinical equipment and clinical information technology on all continents. Ramanujan has held scientific, technical and laboratory manager positions at Chrysler Corp., GE, Kodak, Carestream and Intrinsiq Materials. She holds 28 issued US patents. She got a doctorate. in Electrical Engineering from the University of Michigan.

Dimitri Chernyak, Ph.D., is President and CEO of Intelon Optics. He has worked in the medical device industry for over 20 years and has extensive experience in product research, business development and scale-up. He has led several R&D organizations, working closely with cross-functional teams (including clinical research, medical and regulatory affairs) to bring products to market. His industry experience includes VISX, AMO, Abbott and Johnson & Johnson. Chernyak obtained his doctorate. at the University of California, Berkeley.

Felix Kim is the founder and CEO of Ovitz, the million dollar winner of the Luminate accelerator. Ovitz has developed an individualized vision-enhancing contact lens innovation that dramatically improves the quality of people’s vision: clarity, contrast and depth perception.

Edgar Janunts, Ph.D., is the founder of Akknatek. Janunts graduated from the International Max Planck Research School for Optical Imaging (IMPRS-OI) in Erlangen, Germany, followed by an internship at Harvard Medical School and Massachusetts General Hospital in Boston and EPFL in Lausanne, in Swiss. After obtaining his doctorate. diploma, he returned to Germany and continued his research and development activities in the field of ophthalmology and ophthalmic optics at the University of Saarland.

Adam Wax, Ph.D., is co-founder and president of Lumedica, which was launched in 2014 with the vision of building low-cost biomedical imaging systems for research and clinical use. Wax holds a doctorate in physics from Duke University and joined the faculty in 2002 as a professor of biomedical engineering. His research focuses on the application of optical spectroscopy techniques to biomedical applications, including the early detection of cancer, retinal disease and potentially Alzheimer’s disease. The innovative techniques resulting from his research have made it possible to reduce the cost of optical coherence tomography imaging tools in the hope of increasing access to imperative medical screening. He is a member of OSA, SPIE and AIMBE. In 2020, he was selected as editor-in-chief of Optics Engineering, a peer-reviewed SPIE journal specializing in optics and photonics research.

Susana Marcos, Ph.D., is co-founder of 2EyesVision, launched in 2015. Marcos is also Director of the Center for Visual Science and Professor of Optics at the Institute of Optics at the University of Rochester, as well as Professor of Ophthalmology at the Flaum Eye Institute in Rochester. She has published over 180 research papers and is the inventor of 20 patent families, 14 of which are licensed to industry. His research was essential for the spin-off companies Plenoptika and 2EyesVision. She is a recognized researcher in the field of visual optics and ocular imaging and a pioneer in the development of new techniques for the evaluation of the eye, in particular: retinal imaging instruments, aberrometers, adaptive optics, imaging of the anterior segment of the eye and intraocular lens designs. She obtained her baccalaureate and her doctorate. degrees in physics from the University of Salamanca, Spain.


About Luminate:

Enlighten is the world’s largest startup accelerator for optical, photonics and imaging applications. Five companies in its portfolio are solving pressing challenges in the global ophthalmic diagnostics and surgical devices market by bringing emerging technologies to ophthalmologists that will expand their practice options, options and patient satisfaction.


Source link

]]>
CDC expects to identify omicron COVID-19 variant ‘quickly’ if it arrives in the United States https://web-xpress.com/cdc-expects-to-identify-omicron-covid-19-variant-quickly-if-it-arrives-in-the-united-states/ Sat, 27 Nov 2021 17:01:00 +0000 https://web-xpress.com/cdc-expects-to-identify-omicron-covid-19-variant-quickly-if-it-arrives-in-the-united-states/ through: Nathaniel Rodriguez, Nexstar News Wire Posted: November 27, 2021 / 11:01 CST / Update: November 27, 2021 / 10:39 AM CST The CDC made the announcement shortly after the World Health Organization (WHO) classified the omicron variant, or B.1.1.529, as a variant of concern. (Getty Images) ATLANTA (WFLA) – The Centers for Disease Control […]]]>

The CDC made the announcement shortly after the World Health Organization (WHO) classified the omicron variant, or B.1.1.529, as a variant of concern. (Getty Images)

ATLANTA (WFLA) – The Centers for Disease Control and Prevention is monitoring the emergence of a new highly transmissible variant of COVID-19 identified in South Africa.

The CDC said that “if” this variant – known as the omicron variant – emerges in the United States, it should be identified “quickly.”

“No case of this variant has been identified in the United States to date,” the CDC wrote in a statement on Friday. “The CDC is following the details of this new variant, first reported to WHO by South Africa. We are grateful to the South African government and its scientists who have openly communicated with the global scientific community and continue to share information on this variant with the US Department of Health and Human Services and the CDC. We are working with other public health and industry partners in the United States and around the world to learn more about this variant, while continuing to monitor its progress.

“The CDC is constantly monitoring variants and the US Variant Monitoring System has reliably detected new variants in this country. We expect Omicron to be identified quickly, if it emerges in the United States.

The CDC made the announcement shortly after the World Health Organization (WHO) classified the omicron variant, or B.1.1.529, as a variant of concern. Health experts say the mutated properties of the variant allowed it to spread rapidly among younger individuals, causing COVID-19 levels to rise rapidly in South Africa after a period of poor growth.

Such concerns have prompted the United States and the European Union to enact a travel ban from South Africa and other countries to contain the virus. However, experts say these bans will not stop the virus from reaching the West.

“Travel restrictions may delay but not prevent the spread of a highly transmissible variant,” Mark Woolhouse, professor of infectious diseases at the University of Edinburgh, said in an Associated Press report.

In the meantime, the CDC continues to urge mask wear, social distancing and vaccinations to protect against COVID-19 variants. Travelers to the United States

The Associated Press contributed to this report.

Ongoing coronavirus coverage


Source link

]]>
From tummy tucks to facelifts: pet plastic surgery takes place in Ohio https://web-xpress.com/from-tummy-tucks-to-facelifts-pet-plastic-surgery-takes-place-in-ohio/ Thu, 25 Nov 2021 17:47:57 +0000 https://web-xpress.com/from-tummy-tucks-to-facelifts-pet-plastic-surgery-takes-place-in-ohio/ (WJW) – From “tummy tucks” to “facelifts,” many plastic surgeries that were once the preserve of humans are now performed on pets. It may sound outrageous, but these operations are in fact advanced procedures that can dramatically improve the life of the animal; including a pot-bellied pig named Winnie. “We call it Winnie’s tummy tuck […]]]>

(WJW) – From “tummy tucks” to “facelifts,” many plastic surgeries that were once the preserve of humans are now performed on pets.

It may sound outrageous, but these operations are in fact advanced procedures that can dramatically improve the life of the animal; including a pot-bellied pig named Winnie.

“We call it Winnie’s tummy tuck but it was really a medically necessary operation for her to walk and enjoy being a pig, ”said Lissy Kuhn, at Happy Trails Farm Animal Sanctuary in Ravenna, Ohio.

The pot-bellied pig arrived at the sanctuary weighing well over 400 pounds and was unable to stand, let alone walk.

The loving Guardians of Happy Trails worked with Winnie for over a year to help her lose over 200 pounds, but it only created yet another painful issue.

“She was quickly developing a lot of excess skin and when she started walking she started walking on that excess skin,” Kuhn said.

It was then that the amazing surgeons at the Ohio State University School of Veterinary Medicine performed the abdominoplasty; removing over 10 inches of excess skin allowing Winnie to walk and finally live a happy life.

Other animals have undergone eye work, facelifts and rhinoplasty to improve their quality of life.

Dr Jason Lamb of the Avon Lake Animal Clinic says that although the operations appear cosmetic, they are actually often necessary for the health of the animal.

“We do anatomical variations in dogs, but we do it for medical reasons and not to make the dog prettier,” Lamb said, “Some diseases that we treat in dogs are diseases of the respiratory tract in which are considered brachycephalic dogs typically like your English Bulldogs and Boston Terriers, their noses are usually too small, so they undergo rhinoplasty to open up these airways.

Folds of skin around the eyes and other parts of the body are often removed to reduce painful chronic infections in some breeds.

A Shar-pei must have had “tight” eyes because his eyelashes turned inward.

“You have to remove them because it creates pathology rubbing the cornea,” Lamb said.

Advances in stem cell procedures are also underway at Avon Lake Animal Clinic by harvesting fat from animals.

When these cells are injected back into the animal, they can aid mobility in older pets and improve certain illnesses.

“Stem cells are very regenerative, stem cells are actually able to divide and become something else,” said Dr. Carmen Petti, “I think stem cells are going to become protocols for everything: diabetes, kidney disease. , etc. “

Previously, lipomas required surgery to remove fatty tumors, which could be dangerous for older pets, but less invasive liposuction is now an option for some.

And high-tech endoscopes are being used at the Northview Animal Clinic in North Ridgeville, said Dr. Randy Hutchison, “A lot of dogs that would automatically go straight for surgery because they swallowed something, we can get off and on. actually remove it without resorting to surgery.

Unfortunately, the procedures can be expensive right now, and vets say they should always be carefully considered when weighing the benefits against the risks to the animal.

“You have to assess the medical benefit of it, risk yourself anesthesia,” Lamb said.

Like Winnie’s case, and her tummy tuck which absolutely improved her quality of life.

“Oh my God, the first time we saw her ‘wallowing’ in the mud like a normal pig, it was so wonderful,” Kuhn said. “And now Winnie has been adopted by a very special family.

Latest news


Source link

]]>
Recall of Amgen, Lilly, and Biohaven Migraine Brands Low, Study Finds; Novartis seeks to remake drug launch model – Endpoints News https://web-xpress.com/recall-of-amgen-lilly-and-biohaven-migraine-brands-low-study-finds-novartis-seeks-to-remake-drug-launch-model-endpoints-news/ Tue, 23 Nov 2021 18:39:00 +0000 https://web-xpress.com/recall-of-amgen-lilly-and-biohaven-migraine-brands-low-study-finds-novartis-seeks-to-remake-drug-launch-model-endpoints-news/ Horizon Therapeutics CEO Tim Walbert runs a rare disease company, but he’s also a patient. While his condition is no secret, Walbert first presents himself as the face of a rare disease in Horizon’s new corporate campaign, “It’s Personal”. Or rather, as one of the faces of a rare disease – other Horizon employees will […]]]>

Horizon Therapeutics CEO Tim Walbert runs a rare disease company, but he’s also a patient. While his condition is no secret, Walbert first presents himself as the face of a rare disease in Horizon’s new corporate campaign, “It’s Personal”.

Or rather, as one of the faces of a rare disease – other Horizon employees will also share their stories as patients and caregivers as part of the effort.

Walbert knows the typical long journey of rare disease patients. He was first diagnosed with an autoimmune disease similar to rheumatoid arthritis while a college student, but it was another 10 years before he was diagnosed with a second rare disease. More recently, he unfortunately added the role of caregiver to a child with a rare disease when his 13-year-old son was diagnosed with two autoimmune diseases last year.

Walbert joined Horizon as CEO in 2008 after working at Abbott – now AbbVie – in immunology on the launch of the anti-inflammatory biologic Humira. Prior to that, he worked at Searle, now part of Pfizer, on Celebrex pain medication. The then booming Horizon had only a handful of employees and no office space, literally working from Walbert’s living room.

Lately Horizon has been in tears. Despite a pair of major setbacks with the closure of infusion centers in the event of a pandemic just weeks after its key approval for Tepezza’s thyroid eye disease, and then later when Catalent canceled Tepezza’s manufacturing slots to prioritize production of Covid-19 vaccines, the company reported $ 820 million in Tepezza sales in 2020. This was about 40% of pharma’s record $ 2.2 billion sales in 2020, surpassing 1.3 billion dollars in 2019 sales.

Although “It’s Personal” is Horizon’s first corporate branding effort, the growing pharmaceutical company has long relied on direct-to-consumer advertising as a key part of its go-to-market strategy. He’s also invested heavily in unbranded awareness campaigns, including RareIs, which started as a social media awareness campaign that has grown into a resource and community of support for rare diseases. Platform.

Walbert recently spoke to MarketingRx endpoints editor-in-chief Beth Snyder Bulik on Horizon’s new campaign and the rare personal journey that has helped shape her career.

How did the new “It’s Personal” campaign come about? Can you talk about your personal connection and why you wanted to?

Keep Reading Endpoints With A Free Membership

Unlock this story instantly and join over 123,900 biopharmacy professionals reading Endpoints daily, and it’s free.



Source link

]]>
Childhood obesity: the coming pandemic | Cashmere amount https://web-xpress.com/childhood-obesity-the-coming-pandemic-cashmere-amount/ Sun, 21 Nov 2021 23:09:36 +0000 https://web-xpress.com/childhood-obesity-the-coming-pandemic-cashmere-amount/ Malnutrition is a major public health problem and a complex problem to solve. Undernutrition and obesity are both high risks of premature death and disability. On the one hand, undernutrition levels have decreased by 10 percent according to the National Family Health Survey (NFHS) 2016, there is a marked increase in the frequency of obesity […]]]>

Malnutrition is a major public health problem and a complex problem to solve. Undernutrition and obesity are both high risks of premature death and disability. On the one hand, undernutrition levels have decreased by 10 percent according to the National Family Health Survey (NFHS) 2016, there is a marked increase in the frequency of obesity on the other side of the spectrum, which is an independent risk factor for various noncommunicable diseases. diseases such as hypertension, diabetes mellitus and the resulting heart attacks and strokes.

Obesity has reached epidemic proportions worldwide and its prevalence has doubled over the past two decades. Over the past 5 years, most developing countries have reported prevalence rates of obesity (including overweight)> 15% in children and adolescents aged 5-19 years. Childhood obesity is increasing at an alarming rate in India, causing diseases in adults among young people, such as high blood pressure, type 2 diabetes (T2DM), heart disease and joint disorders.

The increasing frequency of obesity in children is due to the following factors:

Unhealthy diet

The comparatively low cost of high-energy foods, improved purchasing power, TV commercials targeting children, and junk food sold in school canteens are shifting children’s eating habits from healthy foods to fatty fried and processed foods.

Parents’ professional status

Parents these days are working and having busy lives. They are often overworked and it is easy to let children order “quick meals” and have little time to monitor a balanced diet for children.

Lack of physical activity

Move from outdoor play to indoor entertainment; watching television, the Internet and playing computer games have all contributed to the increase in obesity in children. Children no longer want to ride a bicycle, and parents think it is safer to drive a car than a bicycle in a chaotic city.

Academics

The growing burden of academic competitiveness among students has led to a decrease in participation in sports and all other forms of physical activity. This is especially true for girls who have been sedentary since school years. Numerous studies conducted in India show that women have more obesity and metabolic syndrome than men.

Improved socio-economic status

The increase in purchasing power in the form of daily allowances (pocket money) to purchase food / snacks available in school cafeterias or nearby fast food restaurants could be a major reason for this.

Wrong parenting approach

Parents in India and other developing countries generally have the misconception that an obese child is a healthy child. And that if the child is big, the “big baby” will disappear over time. In an effort to keep the child “healthy”, he is overfed. Many of these children remain obese their entire lives.

Technology

More importantly, with the advancement of technology, especially in the field of entertainment, more time has been spent watching television, computers and video games at the expense of sports and physical activity, making it a sedentary lifestyle for children.

The worrying situation is that Covid lockdowns have led to an increase in various disorders in children, such as increased screen time, a sedentary lifestyle and its detrimental consequences on weight and behavior. The increase in screen time among children as a result of online classes has resulted in eye strain, behavioral changes, sleep disturbances, and weight gain.

Due to the confinement, children remain confined to their homes and their only hobby is watching videos on cell phones and / or other gadgets. On the other hand, people, in general, lack knowledge about a balanced diet and daily requirements for energy, carbohydrates, fatty proteins, macro and micronutrients. They eat whatever they can afford and it pleases their taste buds. People eat as much as they can afford without worrying about excess or lack of calories.

Research reveals obese children under confinement in Italy ate more junk food, watched more television at the expense of physical activity. “First of all, online classes increased stress and a sedentary lifestyle in children. On average, locking increased screen time in children up to three times compared to the pre-covid era. “

This study, published in April on obesity, looked at 41 overweight children confined in March and April in Verona, Italy. Compared to the behavior recorded a year earlier, the children ate one extra meal per day; slept an extra half hour a day; added nearly five hours a day in front of phone, computer and television screens; and dramatically increased their consumption of red meat, sugary drinks and junk food. Physical activity, on the other hand, declined by more than two hours per week and the amount of vegetables consumed remained unchanged.

There is no doubt that the lockdowns that have been put in place across the world to contain the COVID-19 pandemic have had a negative impact on children’s diet, sleep and physical activity, according to news. research.

The Body Mass Index (BMI) is a measure that uses height and weight to determine whether a person is healthy or obese. An ideal BMI is between 18.5 and 24.9 and over 30 is defined as obesity.

In most obese children, environmental and hereditary factors play a major role. Only less than 1% of obese children have an underlying pathology of childhood obesity.

Childhood obesity is associated with significant complications. Obesity is responsible for the development of insulin resistance due to the deposition of fat in skeletal muscles and the liver. Insulin resistance predisposes a person to develop type 2 diabetes, polycystic ovary syndrome, metabolic syndrome, and nonalcoholic fatty liver disease.

The cardiovascular effects of obesity in children are due to a higher prevalence of dyslipidemia, hypertension and the resulting atherosclerosis, especially in the coronary arteries that supply blood to the muscle and tissues of the heart. Childhood obesity is one of the main risk factors for premature coronary atherosclerosis and heart attack at a young age.

In addition, obesity is a risk factor for many orthopedic conditions such as flatfoot, genu valgum and osteoarthritis. The most debilitating complication of obesity is the slip of the capital femoral epiphysis which results in groin pain and abnormal gait.

Obesity is associated with frequent gastrointestinal complications, including gastroesophageal reflux disease and non-alcoholic fatty liver disease. Fatty liver disease is present in 40 percent of obese children. About 2% of obese children develop gallstones and can lead to life-threatening complications like pancreatitis.

This higher incidence of obesity and associated complications requires mass awareness programs.

Malnutrition is the leading cause of death and disease in the world. The developmental, economic, social and medical impacts of malnutrition are severe and long lasting.

A balanced diet is defined as an adequate and appropriate nutritional intake of foods that provide all macro and micro nutrients in desirable amounts. Inexpensive foods tend not to be healthy foods; we need government policies that make healthy food more available and affordable. We need to see changes in the public sector so that government organizations ban all unhealthy food, especially outside or inside schools.

Health education and investment in food research will be critical over the next five years. “One of the biggest obstacles is the availability of good food, which is always dictated by the big producers. We need to find a way to engage with the food industry to change the content of food products. In some countries, the desire to eat the right food cannot be satisfied due to the choice of food available in the supermarket and its price.

It is high time for a thorough review of diet and technology, and people need to know how food is produced, how many calories it contains, and what percentage of carbohydrates, fat and protein in particular is food. . It’s time to educate people on the benefits of polyunsaturated fats and the cons of saturated fats.

The top three reasons for heart attacks in young people are obesity, smoking and drug addiction and it is time to deal with them holistically as soon as possible so that many young lives can be saved.

Depending on the length of confinement, the excess weight gained may not be easily reversible and may contribute to obesity in adulthood if healthier behaviors are not restored. “This is because obesity in children and adolescents tends to track over time and predict weight status in adulthood.”

Generally speaking, Kashmiri people have a good price and good accessibility to food. The erratic eating habit in Kashmir is one of the main reasons for the increase in obesity among the masses and children in general. The people of Kashmir are voracious meat eaters and high consumption of butter, ghee, poultry and its products has increased the increasing levels of obesity and its subsequent metabolic complications.

For the prevention of obesity, especially in childhood, the emphasis should be on a healthy and active lifestyle and on creating a stimulating environment that helps young people to recognize their own worth and respect cultural eating habits. It is recognized that obesity, eating disorders, dangerous weight loss, nutritional deficiencies and height discrimination are all interrelated and need to be addressed holistically, thus requiring a multi-layered approach.

Conclusion

Childhood obesity is associated with a number of health problems such as hypertension, T2D and high cholesterol, stroke, heart attacks, which were once reserved for adults.

It is also associated with other significant morbidities, including gallstones, dyslipidemia, obstructive sleep apnea syndrome, early puberty or menarche, eating disorders, skin infections, orthopedic disorders, asthma and other respiratory disorders.

In addition to having a medical impact on the individual, childhood obesity also has a negative impact on the psychosocial development of the child as well as on the financial economy of the individual household as well as the country.

Community-based interventions should aim to provide an enabling environment for children to adopt healthy lifestyles, promote healthy food alternatives, and raise awareness of increased physical activity.

Other sporting activities should be encouraged across Jammu and Kashmir and the government will develop all facilities for these activities in villages and towns.

(The author is Professor of Pediatrics, GB Pant Children Hospital Srinagar)


Source link

]]>
Pandemic doctors pushed before public eyes to help quell COVID-19 myths and falsehoods https://web-xpress.com/pandemic-doctors-pushed-before-public-eyes-to-help-quell-covid-19-myths-and-falsehoods/ Sat, 20 Nov 2021 09:00:00 +0000 https://web-xpress.com/pandemic-doctors-pushed-before-public-eyes-to-help-quell-covid-19-myths-and-falsehoods/ The power of medical advice was previously harnessed by dressing ordinary men in white coats and stethoscopes to promote the lie that cigarettes are safe. And it worked for years because these pitchmen were designed to resemble our predominant symbol of public trust: the doctor. This efficiency still exists, but in Ian Hanomansing’s new book, […]]]>



The power of medical advice was previously harnessed by dressing ordinary men in white coats and stethoscopes to promote the lie that cigarettes are safe. And it worked for years because these pitchmen were designed to resemble our predominant symbol of public trust: the doctor.

This efficiency still exists, but in Ian Hanomansing’s new book, Pandemic Projector, it is used by the authentic medical profession, and not to hurt people but to help them, guide them and reassure them and to fight the lies, paranoia, fake news and fairy tales spread about the pandemic of COVID-19.

Light in the event of a pandemic

“/>

Spotlight on the pandemic

All the benefits of Spotlight on the pandemic support a future student in infectious diseases and public health at the University of British Columbia

Spotlight on the pandemic is the well-told story of nine infectious disease physicians who, in a matter of months, have gone from anonymity to stardom in their willful fight against COVID misinformation. For thousands of hours, each of them has used social media (especially Twitter) and news media to fight the uninformed and fight the fanciful with facts. They still do – and do it for free.

Hanomansing, longtime CBC reporter and co-host of The National, writes authoritatively and candidly about how these doctors across the country are helping us overcome this disturbing threat to our lives and mental health. As Hanomansing acknowledges, they (and others like them) are our defense against the offensive and mindless voices of prejudice, pseudoscience, absurd advice, quackery, witchcraft and religious fanaticism. And they continue to educate and reassure us despite personal attacks on their character and well-being.

Dr Zain Chagla from Hamilton told Hanomansing: “I can say it baffles me when all of us – over ten years of training, over ten years of clinical practice, constantly looking at the ever-changing evidence every day – that someone is firing us saying “You are completely wrong because I saw this YouTube video.” “It’s almost funny …”

Saskatoon’s Dr. Alexander Wong recounts how, in reaction to one of his tweets, someone called him a Nazi. His response is priceless: “I’m a Nazi? Did you see me? Come on. I’m a bald Asian dwarf, man.”




Dr Chagla says: “There are certainly trolls on Twitter who will call us very disgusting names or call us murderers. ”

Dr Isaac Bogoch from Toronto talks about how he receives some cool emails, but some that are far from nice. “Some days I’m (called) a shill for (Canadian Prime Minister) Trudeau, other days I’m a shill for (Premier of Ontario) Doug Ford, but every day I’m a dirty Jew.” He also received death threats, like others. “The police took him very seriously,” he wrote. “They were great.”

Dr Sumon Chakrabarti from Toronto said, “Yes, I get a lot of weird emails. Of course, the garden variety ‘Go back to where you came from’ or ‘You smell like curry.’ ”

Edmonton’s Dr Lynora Saxinger, who as of mid-November had more than 26,000 Twitter followers, says hurtful comments about her are “nothing compared to what people in public health get.”



<p>Darryl Dyck / Canadian Press Files Dr. Srinivas Murthy, who works in the intensive care unit at BC Children’s Hospital, is one of nine doctors described in Hanomansing’s book.</p>
<p>“/><br />
						</a><figcaption wp_automatic_readability=

Darryl Dyck / Canadian Press Files Dr. Srinivas Murthy, who works in the intensive care unit at BC Children’s Hospital, is one of nine doctors described in Hanomansing’s book.

But overall, all physicians agree that overall their experience with the public is and has been clearly positive, that the negative exchange is less than 10%. Dr. Lisa Barrett of Halifax goes one step further by calling the responses she received very favorable.

“Twitter has been very positive,” said Dr. Fatima Kakkar of Montreal.

An entire chapter is a biography of these doctors. Sometimes we worked with the very popular Dr. Anthony Fauci at the National Institutes of Health in Maryland. Another wanted to be a doctor from the age of five, another enjoys basketball, another was in Liberia during the Ebola outbreak and saw “local doctors die in droves” due to a lack of personal protective equipment. Yet another spent months in Zimbabwe in 2001 watching AIDS patients die from lack of resources. And another, in Zambia in 2005, had to end the life of a dying child to save another because there was only enough oxygen for one.

For these nine doctors, their mass communications journey began when they simultaneously received notification from ProMED Mail, a service of the International Society for Infectious Diseases that alerts specialists to infectious disease outbreaks around the world. The message was posted at one minute to midnight on December 30, 2019: “Undiagnosed pneumonia – China”.

Dr Susy Hota of Toronto remembers when she received the alert from ProMED: “We know… a pandemic can happen. An unknown group of serious respiratory illnesses from China is sort of the prototype event you are looking for. The unease never left me after that. ”

But China was far away, and life continued as usual in Canada – even when COVID hit Italy the following February, with thousands stranded, hospitals overwhelmed with sick and dying, and more than 190 doctors and nurses. died from the virus.

According to Dr Srinivas Murthy of Vancouver: “Italy has claimed hundreds and hundreds of lives in just a few days. I think this was pretty much our ‘Come to Jesus moment’. This is going to be a big deal.”

Barry Craig loves curry.

If you enjoy coverage of the Manitoba arts scene, help us do more.
Your contribution of $ 10, $ 25 or more will allow Free Press to deepen our reporting on theater, dance, music and galleries while ensuring that the widest possible audience can access our artistic journalism.

BECOME A SUPPORT FOR ARTISTIC JOURNALISM
Click here to learn more about the project.


Source link

]]>
ProQR to Virtual Webcast Analysis https://web-xpress.com/proqr-to-virtual-webcast-analysis/ Thu, 11 Nov 2021 12:03:15 +0000 https://web-xpress.com/proqr-to-virtual-webcast-analysis/ LEIDEN, The Netherlands and CAMBRIDGE, Mass., November 11, 2021 (GLOBE NEWSWIRE) – ProQR Therapeutics NV (PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a virtual analysts event on November 18, 2021, from 12:00 p.m. to 2:00 p.m. ET to highlight its […]]]>

LEIDEN, The Netherlands and CAMBRIDGE, Mass., November 11, 2021 (GLOBE NEWSWIRE) – ProQR Therapeutics NV (PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a virtual analysts event on November 18, 2021, from 12:00 p.m. to 2:00 p.m. ET to highlight its clinical stage pipeline programs and the Axiomer® RNA editing platform.

ProQR’s Leadership to Highlight Key Advances in Its Clinical-Stage Pipeline, Including Phase 1/2 Data Overview sepofarsen extension study. The Company will also highlight the sepofarsen program more broadly, summarizing program data to date, sharing a patient’s perspective from the phase 1/2 trial, and examining phase 2/3. Enlighten test design and assumptions. QR-421a, QR-1123, QR-504a and RNA editing platform technologies will also be presented.

Program

Welcome Sarah Kiely, Vice President of Public Relations and Corporate Communications
Vision and strategy Daniel A. de Boer, Managing Director
Clinical programs Aniz Girach, MD, Chief Medical Officer
RNA Toolkit Gérard Platenburg, Director of Innovation
Questions and answers led by Smital Shah, Commercial and Financial Director

Webcast information

Attendees can pre-register for the live stream and access the archived webcast through this webcast link or from the “Investors and Media” section of the ProQR website (www.proqr.com) under “Events”. Archived webcasts will be available for approximately 30 days after the presentation date.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of serious rare genetic diseases such as congenital Leber 10 amaurosis, Usher syndrome and retinitis pigmentosa. Based on our proprietary RNA repair platform technologies, we are developing our pipeline with patients and their loved ones in mind.
Learn more about ProQR at www.proqr.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by words such as “anticipate”, “believe”, “might”, “estimate”, “expect”, “objective”, “Intend”, “look forward to”, “may”, “plan”, “potential”, “anticipate”, “plan”, “should”, “will”, “would” and similar expressions. These forward-looking statements include, without limitation, statements regarding the analyst’s event. Forward-looking statements are based on the beliefs and assumptions of management and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for a number of reasons, including, without limitation, risks, uncertainties and other factors in our documents filed with the Securities and Exchange Commission, including including certain sections of our annual report filed on Form 20-F. In view of these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, unless required by law. .

ProQR Therapeutics SA

Investor contact:
Sarah kiely
ProQR Therapeutics SA
T: +1 617 599 6228
[email protected]
Where
Hans vitzthum
LifeSci Advisors
T: +1 617 430 7578
[email protected]

Media contact:
Cherilyn Cecchini, MD
LifeSci Communications
Phone. : +1 646 876 5196
[email protected]

ProQR-Therapeutics-NV-.png


Source link

]]>
Oyster Point Pharma to Present Data at American Academy of Ophthalmology 2021 Annual Meeting | New https://web-xpress.com/oyster-point-pharma-to-present-data-at-american-academy-of-ophthalmology-2021-annual-meeting-new/ Tue, 09 Nov 2021 12:01:00 +0000 https://web-xpress.com/oyster-point-pharma-to-present-data-at-american-academy-of-ophthalmology-2021-annual-meeting-new/ PRINCETON, NJ, November 09, 2021 (GLOBE NEWSWIRE) – Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of leading pharmaceutical therapies to treat the ophthalmic diseases, today announced several scientific presentations at the 2021 American Academy of Ophthalmology (AAO) annual meeting to be held in New Orleans, […]]]>

PRINCETON, NJ, November 09, 2021 (GLOBE NEWSWIRE) – Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of leading pharmaceutical therapies to treat the ophthalmic diseases, today announced several scientific presentations at the 2021 American Academy of Ophthalmology (AAO) annual meeting to be held in New Orleans, LA, November 12-15, 2021.

“The American Academy of Ophthalmology is the world’s largest association of ophthalmologists and surgeons whose mission is to improve lives by advocating for patients and the public, leading ophthalmic education, and advancing the profession of ophthalmology. ‘ophthalmology. Said Marian Macsai, MD, medical director of Oyster Point Pharma. “We are delighted to share a number of presentations of data from company-sponsored clinical trials at this year’s meeting, highlighting the newly approved TYRVAYATM nasal spray (varenicline solution) for the treatment of signs and symptoms of dry eye. “

Documents / Posters

Title: ONSET-2 Phase 3 Trial of OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease Presenter: Marjan Farid, MD Location: Morial Convention Center, Room 255-257 Date / Presentation time: November 14 at 8:48 am-8:55 am CST

Title: Clinical Outcomes of Clinical Signs of OC-01 Nasal Spray in Dry Eye by Basic Stratification Factors – Combined ONSET-1 & -2 Presenter: John D Sheppard MD Location: Morial Convention Center, Hall C (Poster Theater and Lounge ) Date / Time of Presentation: November 14 at 3:45 p.m. – 4:45 p.m. CST

Title: OC-01 (Varenicline Solution) Clinical Signs Nasal Spray Results in Dry Eye Disease by Age and Use of Artificial Tears – A Subgroup Analysis Presenter: Alice T. Epitropoulos, MD Location: Virtual Presentation Date / Time : On demand

About dry eye and the role of the tear film Dry eye is a chronic disease that affects approximately 38 million people in the United States and is increasing in prevalence.1,2 It can cause persistent stinging, scratching, burning sensations, sensitivity to light, blurred vision and eye strain. Dry eye is a multifactorial disease of the ocular surface characterized by rupture of the tear film. The human tear film is a complex mixture of more than 1,500 different proteins, including growth factors and antibodies, as well as many classes of lipids and mucins.3 The natural tear film protects and lubricates the eyes, eliminates particles foreign, contains growth factors and antimicrobial agents. components and creates a smooth surface that forms the primary refractive surface of the eye.

About TYRVAYA ™ (varenicline solution) Nasal Spray TYRVAYA (varenicline solution) Nasal Spray 0.03 mg (formerly called nasal spray OC-01) is a highly selective cholinergic agonist that is approved by the FDA to treat signs and symptoms of dry eye as a multidose nasal spray. The parasympathetic nervous system, the body’s “rest and digest” system, controls tear film homeostasis in part through the trigeminal nerve, which is accessible through the nose. The efficacy of TYRVAYA nasal spray in dry eye is believed to be the result of varenicline activity at the heteromeric nicotinic acetylcholine receptor (nACh) subtype (s) where its binding produces agonist activity. and activates the trigeminal parasympathetic pathway resulting in increased basal tear film production as a treatment for dry eye. Varenicline binds with high affinity and selectivity to neuronal nicotinic acetylcholine receptors 4β2, α4α6β2, α3β4, α3α5β4 and α7. The exact mechanism of action is unknown at this time.

Important Safety Information of TYRVAYATM The most common adverse reaction reported in 82% of patients was sneezing. Events reported in 5-16% of patients were cough, throat irritation, and instillation site (nose) irritation. There are no contraindications associated with TYRVAYATM Nasal Spray (varenicline solution).

Please see full prescribing information at www.tyrvaya-pro.com/prescriptioninformation.

About Oyster Point Pharma, Inc. Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of leading pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA approval for TYRVAYATM nasal spray (varenicline solution) for the treatment of signs and symptoms of dry eye. Oyster Point has a growing portfolio of clinical and preclinical programs and continues to expand its research and development portfolio through internal innovation and external collaborations. Oyster Point continually strives to advance cutting-edge science and provide therapies to address the unmet needs of patients with ophthalmic disease and the eye care professionals who care for them. For more information visit www.oysterpointrx.com and follow @OysterPointRx on Twitter and LinkedIn.

Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 which reflect Oyster Point Pharma’s (the “Company” or “our”) current beliefs, expectations and assumptions regarding the future. of the Company’s business, our future plans and strategies, regulatory approvals, preclinical and clinical results, future financial condition and other future conditions. All statements other than statements of historical fact contained in this press release, including express or implied statements regarding management’s plans and objectives for future operations, future operating results and financial condition, strategy commercial, product candidates, regulatory approvals, anticipated future commercialization of the product, planned preclinical studies and clinical trials, expected results of preclinical studies or clinical trials, and their timing and likelihood of success, costs to commercialize expected research and development, are forward-looking statements. The words “if approved”, “may”, “will”, “should”, “should”, “expect”, “plan”, “anticipate”, “could”, “intend”, “Target”, “project”, “- not all statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: our plans and potential for success relating to the commercialization of TYRVAYA; the beneficial characteristics, safety, efficacy and therapeutic effects of TYRVAYA and our preclinical and clinical product candidates; our plans for the further development and manufacture of TYRVAYA and our preclinical and clinical candidates, including potential additional indications or disease areas to be assessed and pursued; when to launch our future preclinical studies or clinical trials; uncertainties inherent in pharmaceutical research and development, including the results of preclinical studies and clinical trials and further analysis of existing data; the likelihood of clinical trials demonstrating the safety and efficacy of our product candidates, and other positive results; the timing or likelihood of registrations and regulatory approvals of TYRVAYA and our clinical and preclinical candidates, including in potential additional indications for TYRVAYA and potential filings in other jurisdictions; our plans and ability to obtain or protect intellectual property rights, including extensions of the terms of existing patents, where applicable; our ability to recruit and retain key personnel necessary to develop and market our product candidates, if approved, and to grow our business; existing regulations and regulatory developments in the United States and other jurisdictions; our continued reliance on third parties to conduct preclinical studies and additional clinical trials of our product candidates, and for the manufacture of our product candidates for potential commercialization and for preclinical studies and clinical trials; the impact of the COVID-19 pandemic on our activities, operations and regulatory and clinical development timelines; the accuracy of our estimates of expenses, future revenues, capital requirements and additional financing requirements; our financial performance; market conditions; the adequacy of our existing capital resources to fund our future operating expenses and capital expenditure needs; and other risks described in the “Risk Factors” section included in our public documents that we have filed and will make with the Securities and Exchange Commission (SEC). The Company is providing the information contained in this press release as of this date and does not undertake to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Investor Contact Tim McCarthy LifeSci Advisors, LLC (212) 915-2564 investors@oysterpointrx.com

Media Contact Sheryl Seapy Real Chemistry (213) 262-9390 sseapy@realchemistry.com

Sources:

Scope of the market. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. October 2020.Tsubota K, Pflugfelder S, Liu Z, Baudouin C. Defining dry eye from a clinical perspective. Int J Mol Sci. 2020; 21 (23): 1-24. https://pubmed.ncbi.nlm.nih.gov/33291796/Willcox, MD, Argüeso, P., Georgiev, GA, Holopainen, JM, Laurie, GW, Millar, TJ, … & Jones, L. (2017). TFOS DEWS II tear film report. The ocular surface, 15 (3), 366-403.


Source link

]]>
Ophthalmic trauma, artificial intelligence and disparities mark key themes of AAO 2021 https://web-xpress.com/ophthalmic-trauma-artificial-intelligence-and-disparities-mark-key-themes-of-aao-2021/ Sun, 07 Nov 2021 15:05:52 +0000 https://web-xpress.com/ophthalmic-trauma-artificial-intelligence-and-disparities-mark-key-themes-of-aao-2021/ The American Academy of Ophthalmology conference is scheduled to take place in person and online from November 12-15, 2021. In a hybrid face-to-face and online meeting, the American Academy of Ophthalmology (AAO) will host its 2021 annual conference from Friday, November 12 through Monday, November 15 in New Orleans, Louisiana. All in-person meeting attendees are […]]]>

The American Academy of Ophthalmology conference is scheduled to take place in person and online from November 12-15, 2021.

In a hybrid face-to-face and online meeting, the American Academy of Ophthalmology (AAO) will host its 2021 annual conference from Friday, November 12 through Monday, November 15 in New Orleans, Louisiana.

All in-person meeting attendees are required to show proof of COVID-19 vaccination and must wear masks throughout the conference.

On-demand and live sessions are expected to address trends in the field, including improving eye care disparities in the United States, the impact of COVID-19 on the practice of ophthalmology, and the implications of eye care. technological advances in ophthalmology.

New developments on surgical innovations for ophthalmology and treatments for diseases such as glaucoma, thyroid eye disease (TED) and optic nerve diseases will also be presented.

Several sessions focus on ophthalmic trauma, reflecting a change in the field in recent years, explained James Auran, MD, professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma, in an interview. with The American Journal of Managed Care® (AJMC®).

“There was huge interest [in ophthalmic trauma], and a lot of people have dedicated their lives to it, but they haven’t had traction until recently, ”Auran said. “I guess it just hit a tipping point about 2-3 years ago and here we are.”

The on-demand session in which Auran will participate, “Open Globe Trauma: Surgical Management for the On-Call Ophthalmologist”, is scheduled for Sunday, November 14, 2021 from 3:45 pm to 5:00 pm CDT.

Additional speakers at AAO 2021 will discuss the current state of pediatric ophthalmology, developments in astigmatism, cataracts and cosmetic procedures, as well as physician burnout.

As teprotumumab (Tepezza) is the first and only drug approved for the treatment of PDD, several summaries and sessions will focus on actual data on adherence and adverse reactions reported since its approval in 2020. In one session, Anne Barmettler, MD, director of ophthalmic plastic and reconstructive surgery and associate professor of ophthalmology and visual sciences at Montefiore Medical Center, will provide updates on the drug. His presentation, “Teprotumumab: One Year After FDA Approval – What We Know and What We Don’t Know,” will take place on Sunday, November 14 at 12:12 pm CDT.

Experts will also discuss the advent and use of artificial intelligence in ophthalmology at AAO 2021, with presentations highlighting how it can be integrated into practice and used for screening purposes.


Source link

]]>
Global Corneal and Artificial Corneal Implants Market (2021-2028) – By Type, Transplant Type, Disease Indication, End User, and Geography – ResearchAndMarkets.com https://web-xpress.com/global-corneal-and-artificial-corneal-implants-market-2021-2028-by-type-transplant-type-disease-indication-end-user-and-geography-researchandmarkets-com/ Thu, 04 Nov 2021 15:04:00 +0000 https://web-xpress.com/global-corneal-and-artificial-corneal-implants-market-2021-2028-by-type-transplant-type-disease-indication-end-user-and-geography-researchandmarkets-com/ DUBLIN – (COMMERCIAL THREAD)–The “Artificial Cornea and Corneal Implants Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Type;” Type of transplant; Indication of disease; Final user “ report was added to ResearchAndMarkets.com offer. The artificial cornea and corneal implants market will reach US $ 696.18 million by 2028 compared to US $ […]]]>

DUBLIN – (COMMERCIAL THREAD)–The “Artificial Cornea and Corneal Implants Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Type;” Type of transplant; Indication of disease; Final user “ report was added to ResearchAndMarkets.com offer.

The artificial cornea and corneal implants market will reach US $ 696.18 million by 2028 compared to US $ 421.86 million in 2021; it is expected to grow at a CAGR of 7.4% during 2021-2028.

The report highlights the prevailing trends in the market and the factors driving its growth. The growth of the market is mainly attributed to such factors as the increasing prevalence of eye diseases causing corneal blindness and the significant increase in the elderly population. However, the high cost of ophthalmic surgeries and devices is hampering the growth of the market.

According to the American Academy of Ophthalmology 2021, there is a high demand for cornea donors worldwide, as around 10 million people are in need of corneal transplants. However, the number of transplant recipients greatly exceeds the availability of corneal tissue. In densely populated counties like India, blind cornea patients wait for a cornea transplant for more than 6 months. According to the National Center for Biotechnology Information, about 6.8 million people across the country have poor vision in one eye, and about 1 million people have poor vision in both eyes, caused by diseases of the cornea. In 2019, corneal blindness affected approximately 120,000 people in India, and by the end of 2020, it is estimated that there would be 10.6 million cases of unilateral corneal blindness.

The country needs about 250,000 corneas each year; however, the total number of corneas donated each year is approximately 25,000. According to the General Directorate of Health Services, approximately 25,000 corneal transplants are performed each year at a need of one million dollars. Thus, the shortage of corneal donors, in contrast to the high prevalence of corneal blindness, is expected to provide high growth opportunities for corneal implant manufacturers.

The artificial cornea and corneal implants market, by type, is segmented into human cornea and artificial cornea. Human cornea segment is expected to hold greater market share in 2021. However, artificial cornea segment is expected to register higher CAGR in the market during the forecast period. Based on the type of transplant, the artificial cornea and corneal implants market is segmented into Penetrating Keratoplasty, Endothelial Keratoplasty, and others. The penetrating keratoplasty segment is expected to represent the largest market share in 2021.

However, Endothelial Keratoplasty segment is expected to register the highest CAGR in the market during the forecast period. The artificial cornea and corneal implants market, based on disease indication, is segmented into Fuchs dystrophy, keratoconus, fungal keratitis, and others. The Fuchs Dystrophy segment is expected to represent the largest market share in 2021.

However, the fungal keratitis segment is expected to register the highest CAGR in the market during the forecast period. Based on the end user, the artificial cornea and corneal implants market is segmented into hospitals, specialty clinics and ASCs, and others. The specialty clinics and ASC segment is expected to represent the largest market share in 2021, and furthermore, it is expected to register the highest CAGR in the market during the forecast period.

The reasons to buy

  • Gain and reduce the time required to conduct entry-level research by identifying the growth, size, leading players and segments in the Artificial Cornea and Corneal Implants market.

  • Highlights key business priorities to help companies realign their business strategies.

  • The key findings and recommendations highlight crucial progressive industry trends in the Corneal and Artificial Corneal Implants Market, thereby enabling value chain players to develop effective long term strategies.

  • Develop / modify business expansion plans using a substantial growth offering in developed and emerging markets.

  • Take an in-depth look at the global market trends and outlook associated with the factors driving the market, as well as those hindering it.

  • Improve the decision-making process by understanding the strategies that underpin security interests with respect to customer products, segmentation, pricing, and distribution.

Market dynamics

Conductors

  • Increased prevalence of eye diseases causing corneal blindness

  • Significant increase in the elderly population

Constraints

  • Expensive ophthalmic surgeries and appliances

Opportunities

  • Corneal donor shortage offers opportunities for corneal implant manufacturers

Future trends

Companies mentioned

  • AJL Ophthalmic S.

  • Vision Advancement Network

  • Aurolab

  • Cornée Biosciences Inc.

  • LinkoCare Life Sciences AB

  • Keramed, Inc.

  • EyeYon Medical

  • Florida Lions Eye Bank

  • Corneate Vision

  • CorneaGen

For more information on this report, visit https://www.researchandmarkets.com/r/73khcg


Source link

]]>